ALKS — Alkermes plc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1520262 ·
Last close
$45.45
Market Cap
$7.64B
52W High
$55.67
52W Low
$27.00
ADV30
1,784,120
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 480,132,000 | 385,912,000 | 36,592,000 | 16,287,000 | 4,435,523,000 | 631,314,000 | 2,570,802,000 |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 392,911,000 | 331,333,000 | -48,280,000 | -66,480,000 | 4,258,076,000 | 351,551,000 | 2,506,545,000 |
| Dec 2025 | 384,547,000 | 338,338,000 | 58,104,000 | 49,341,000 | 2,486,993,000 | 388,570,000 | 667,698,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$199,475,000
Investing CF
$-1,741,401,000
Financing CF
$1,492,064,000
CapEx
$-37,822,000
Dividends Paid
—
Buybacks
$-27,696,000
EPS Diluted TTM
$-0.02
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-784,486,000
Inventory
$261,098,000
Receivables
$459,090,000
ST Investments
$124,150,000
EBIT TTM
$174,653,000
Pretax Income TTM
$113,933,000
Interest Exp TTM
$60,720,000
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,753,598,976
EBITDA
$281,691,008
Free Cash Flow
$230,842,368
Enterprise Value
$8,528,815,616
Total Cash
$755,464,000
Total Debt
$1,571,080,960
Shares Out
168,043,540
Trailing EPS
$-0.01
Book Value
$11.10
ROE
-0.0%
ROA
3.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,475,899,000 | 253,956,000 | 241,664,000 | 2,486,993,000 | 667,698,000 | 1,819,295,000 | 520,754,000 |
| Dec 2024 | 1,557,632,000 | 420,636,000 | 367,070,000 | 2,055,567,000 | 590,590,000 | 1,464,977,000 | 439,124,000 |
| Dec 2023 | 1,663,405,000 | 414,122,000 | 355,757,000 | 2,136,223,000 | 933,537,000 | 1,202,686,000 | 401,353,000 |
| Dec 2022 | 1,111,795,000 | -6,089,000 | -158,267,000 | 1,963,978,000 | 920,225,000 | 1,043,753,000 | 21,044,000 |
TTM Snapshot
Revenues TTM
$1,667,652,000
NetIncome TTM
$66,123,000
OpCashFlow TTM
—
Assets (Latest)
$4,393,125,000
Forward EPS
$1.35
Max Pain — expiry 2026-12-18
max pain strike: $42.00 · spot: $46.85 · call oi: 4,580 · put oi: 1,449
Expected Move to 2026-12-18:
±$5.50
(11.74%) —
implied range
$41.35 –
$52.35
· ATM straddle on $47.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $7.67B | $70.07 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $7.36B | $21.12 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.07B | $124.67 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
| CYTK | CYTOKINETICS INC | $7.20B | $51.65 | — |
News headlines (Yahoo Finance, 1h cache)
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
2026-11-16 09:12 · Yahoo
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
2026-11-05 12:00 · Yahoo
Alkermes (ALKS) Stock Could Be Overvalued Following ALKS 7290 Trial Launch
2026-11-04 12:15 · Yahoo
Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ...
2026-11-04 03:04 · Yahoo
Alkermes (ALKS) Q3 2026 Earnings Call Transcript
2026-11-03 21:28 · Yahoo
Alkermes to Present at Upcoming Investor Conferences
2026-11-03 21:00 · Yahoo
What Alkermes (ALKS) Said on Its Q3 Earnings Call
2026-11-03 18:14 · Yahoo
Alkermes plc Q3 2026 Earnings Call Summary
2026-11-03 17:49 · Yahoo
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
2026-11-03 13:30 · Yahoo
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
2026-11-03 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.